Worth reading
69In focus
Scored from 2 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
104000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Exercise status of the First Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clauses)
Who receives how much
Shares issued during the month: 104,000 shares (104,000 new shares and 0 treasury shares transferred)
EVO FUND (issued on 24 February 2026)
The lower thin line represents the existing number of shares to which these shares will be added.
Terms of the stock acquisition rights
Exercise price
The exercise price during the subject month ranged from ¥291 to ¥384. Whether adjustment clauses apply and the adjustment floor are Not disclosed
Number of Stock Acquisition Rights
Total issued: 9,860 rights; exercised during the month: 1,040 rights; unexercised at month-end: 8,820 rights
Most recent equity financing
24 February 2026: Issuance of the First Series of Stock Acquisition Rights, with exercise price adjustment clauses, allotted to EVO FUND. Amount: Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Exercise status of the First Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clauses) |
| Number of shares to be issued or disposed of | Shares issued during the month: 104,000 shares (104,000 new shares and 0 treasury shares transferred) |
| Intended allottee | EVO FUND (issued on 24 February 2026) |
| Total number of issued shares | 7,453,350 shares (as of the end of the month preceding the subject month) → Not disclosed |
| Exercise price | The exercise price during the subject month ranged from ¥291 to ¥384. Whether adjustment clauses apply and the adjustment floor are Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 9,860 rights; exercised during the month: 1,040 rights; unexercised at month-end: 8,820 rights |
| Most recent equity financing | 24 February 2026: Issuance of the First Series of Stock Acquisition Rights, with exercise price adjustment clauses, allotted to EVO FUND. Amount: Not disclosed |
Items this document does not state (21)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This is a report on monthly exercise status, and the company has provided no explanation of the reason for the exercise.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.